Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × INDUSTRY × burosumab × Clear all

Phase

Phase 2 2 Phase 4 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Oncogenic osteomalacia 1

Interventions

Zoledronic Acid 17 nilotinib 11 Docetaxel 11 Everolimus 10 Bevacizumab 10 Letrozole 9 enzalutamide 8 Imatinib Mesylate 8 Drug Therapy 8 Capecitabine 8 pegfilgrastim 7 Paclitaxel 7 icotinib 6 Trastuzumab 6 Rituximab 6 Imiquimod 6 Epoetin Alfa 6 Diclofenac 6 Carboplatin 6 Anastrozole 6 exemestane 5 epoetin beta 5 Prednisone 5 Oxycodone 5 Nivolumab 5 Leuprolide 5 Gemcitabine 5 Gefitinib 5 Fulvestrant 5 Erlotinib Hydrochloride 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05357573 2024-07-09

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO

Kyowa Kirin Co., Ltd.

Phase 4 Completed

Oncogenic osteomalacia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡